Edward J Nehus1,2, Chunyan Liu3, Bo Lu4, Maurizio Macaluso2,3, Mi-Ok Kim5. 1. Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 2. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 3. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 4. Division of Biostatistics, The Ohio State University, Columbus, OH, USA. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Abstract
BACKGROUND: Steroid-avoidance protocols have gained popularity in pediatric kidney transplant recipients at low immunologic risk. The long-term safety of steroid avoidance in children with immunologic risk factors remains unknown. METHODS: Pediatric kidney transplant recipients from 2004 to 2014 in the Organ Procurement and Transplantation Network database who received tacrolimus and mycophenolate immunosuppression were investigated. Propensity score matching was used to compare graft survival in 1624 children who received steroid avoidance with 1624 children who received steroid-based immunosuppression. The effect of steroid avoidance on graft failure among immunologic risk strata was estimated using Cox proportional hazards regression in this propensity score-matched cohort. RESULTS: It was observed that 5-year graft survival was mildly improved in children receiving steroid avoidance (84.8% versus 81.2%, P = 0.03). This improvement in graft survival occurred in the first 2 years following transplant, when the hazard ratio (HR) for allograft failure in children receiving steroid avoidance was 0.62 [95% confidence interval (CI) 0.45-0.86]. In contrast, steroid avoidance was not associated with improved allograft survival during Years 2-10 following transplant (HR = 0.93; 95% CI 0.75-1.15). During this time period, HRs (95% CIs) for allograft failure within immunologic risk strata were not significantly different from the null value of 1: repeat kidney transplants, 1.84 (0.84-4.05); African-Americans, 1.02 (0.67-1.56); sensitized recipients, 1.24 (0.63-2.43); recipients of deceased donor kidneys, 1.02 (0.79-1.32); recipients of completely human leukocyte antigen-mismatched kidneys, 0.80 (0.47-1.37); and recipients with pretransplant glomerular disease, 0.94 (0.71-1.23). CONCLUSIONS: In pediatric kidney transplant recipients receiving tacrolimus- and mycophenolate-based immunosuppression, steroid avoidance can be safely practiced in children with immunologic risk factors.
BACKGROUND: Steroid-avoidance protocols have gained popularity in pediatric kidney transplant recipients at low immunologic risk. The long-term safety of steroid avoidance in children with immunologic risk factors remains unknown. METHODS: Pediatric kidney transplant recipients from 2004 to 2014 in the Organ Procurement and Transplantation Network database who received tacrolimus and mycophenolate immunosuppression were investigated. Propensity score matching was used to compare graft survival in 1624 children who received steroid avoidance with 1624 children who received steroid-based immunosuppression. The effect of steroid avoidance on graft failure among immunologic risk strata was estimated using Cox proportional hazards regression in this propensity score-matched cohort. RESULTS: It was observed that 5-year graft survival was mildly improved in children receiving steroid avoidance (84.8% versus 81.2%, P = 0.03). This improvement in graft survival occurred in the first 2 years following transplant, when the hazard ratio (HR) for allograft failure in children receiving steroid avoidance was 0.62 [95% confidence interval (CI) 0.45-0.86]. In contrast, steroid avoidance was not associated with improved allograft survival during Years 2-10 following transplant (HR = 0.93; 95% CI 0.75-1.15). During this time period, HRs (95% CIs) for allograft failure within immunologic risk strata were not significantly different from the null value of 1: repeat kidney transplants, 1.84 (0.84-4.05); African-Americans, 1.02 (0.67-1.56); sensitized recipients, 1.24 (0.63-2.43); recipients of deceased donor kidneys, 1.02 (0.79-1.32); recipients of completely human leukocyte antigen-mismatched kidneys, 0.80 (0.47-1.37); and recipients with pretransplant glomerular disease, 0.94 (0.71-1.23). CONCLUSIONS: In pediatric kidney transplant recipients receiving tacrolimus- and mycophenolate-based immunosuppression, steroid avoidance can be safely practiced in children with immunologic risk factors.
Authors: R Boardman; J Trofe; R Alloway; C Rogers; P Roy-Chaudhury; M Cardi; S Safdar; B Groene; J Buell; M Hanaway; M Thomas; W Alexander; R Munda; E S Woodle Journal: Transplant Proc Date: 2005-03 Impact factor: 1.066
Authors: J C Magee; M L Barr; G P Basadonna; M R Johnson; S Mahadevan; M A McBride; D E Schaubel; A B Leichtman Journal: Am J Transplant Date: 2007 Impact factor: 8.086
Authors: José Oberholzer; Eunice John; Adisorn Lumpaopong; Giuliano Testa; Howard N Sankary; Leslie Briars; Kerri A Kraft; Peter S Knight; Priya Verghese; Enrico Benedetti Journal: Pediatr Transplant Date: 2005-08
Authors: E Steve Woodle; Rita R Alloway; Joseph F Buell; J Wesley Alexander; Rino Munda; Prabir Roy-Chaudhury; M Roy First; Michael Cardi; Jennifer Trofe Journal: Am J Transplant Date: 2005-11 Impact factor: 8.086
Authors: M M Sarwal; R B Ettenger; V Dharnidharka; M Benfield; R Mathias; A Portale; R McDonald; W Harmon; D Kershaw; V M Vehaskari; E Kamil; H J Baluarte; B Warady; L Tang; J Liu; L Li; M Naesens; T Sigdel; Janie Waskerwitz; O Salvatierra Journal: Am J Transplant Date: 2012-06-13 Impact factor: 8.086
Authors: Angela Delucchi; Marcela Valenzuela; Mario Ferrario; Ana Maria Lillo; J Luis Guerrero; Eugenio Rodriguez; Francisco Cano; Gabriel Cavada; Jorge Godoy; Jorge Rodriguez; C Gloria Gonzalez; Erwin Buckel; Luis Contreras Journal: Pediatr Transplant Date: 2007-11
Authors: Nina Mann; Daniela A Braun; Kassaundra Amann; Weizhen Tan; Shirlee Shril; Dervla M Connaughton; Makiko Nakayama; Ronen Schneider; Thomas M Kitzler; Amelie T van der Ven; Jing Chen; Hadas Ityel; Asaf Vivante; Amar J Majmundar; Ankana Daga; Jillian K Warejko; Svjetlana Lovric; Shazia Ashraf; Tilman Jobst-Schwan; Eugen Widmeier; Hannah Hugo; Shrikant M Mane; Leslie Spaneas; Michael J G Somers; Michael A Ferguson; Avram Z Traum; Deborah R Stein; Michelle A Baum; Ghaleb H Daouk; Richard P Lifton; Shannon Manzi; Khashayar Vakili; Heung Bae Kim; Nancy M Rodig; Friedhelm Hildebrandt Journal: J Am Soc Nephrol Date: 2019-01-17 Impact factor: 10.121